Formulation and Evaluation of Glipizide

8/10/2019 Formulation and Evaluation of Glipizide

1/25

Review of Literature

Drug profile

Diltiazem Hydrochloride

Synonym : Cardizem

CAS No : 33286-22-5

Chemical Name : (2S-Cis)3- (Acetyloxy)-5-[2-(Dimethylamino)ethyl]-

2,3-dihydro-2-(4-Methoxyphenyl) -1,5-benzo thiazepin

4(5H)-One HydrochlorideMolecular Structure :

Molecular Formulae : C22H26N2O4S.Hcl

Molecular Weight : 450.98 gm

Category : Calcium Channel Blocker, Anti Hypertensive

Solubility : Soluble in Water, Methanol, Formic Acid

Appearance : White to Off White Powder

Long Term Storage : +20C

Purity : 99% (HPLC)

Log P Value : 4.53


2/25

Brand Names

Cardizem

CardizemCD

CardizemLA

CardizemSR

Cartia XT

Dilacor XR

Dilt-CD

Mechanism:

Diltiazem is a potent vasodilator, increasing blood flow and variably decreasing the

heart rate via strong depression of A-V node conduction. Its pharmacological activity is

somewhat similar to verapamil. Potent vasodilator of coronary vessels. Vasodilator of

peripheral vessels. This reduces peripheral resistance and afterload.

Negative inotropic effect : Diltiazem causes a modest decrease in heart muscle contractility

and reduces myocardium oxygen consumption.

Negative chronotropic effect: Diltiazem causes a modest lowering of heart rate. This effect

is due to slowing of the SA (sinoatrial) node. It results in reduced myocardium oxygen

consumption.

Negative dromotropic effect : By slowing conduction through the AV (atrioventricular)

node, diltiazem increases the time needed for each beat. This results in reduced

myocardium oxygen consumption by the body.


3/25


4/25

Contra-Indications And Precautions:

CHF Patients with reduced ventricular function may not be able to counteract the

inotropic and chronotropic effects of diltiazem, the result being an even higher

compromise of function.

SA node or AV conduction disturbances : Use of diltiazem should be avoided in patients

with SA or AV nodal abnormalities, because of its negative chronotropic and

dromotropic effects

Low blood pressure : Patients with systolic blood pressures below 90 mm Hgshould not be treated with diltiazem.

Wolff-Parkinson-White syndrome : Diltiazem may paradoxically increase ventricular

rate in patients with WPW syndrome because of accessory conduction pathways.

Drug Interactions :

Beta-blockers : Intravenous diltiazem should be used with caution with beta-

blockers because, while this combination is most therapeutically beneficial, there are rare

instances of dysrhythmia and AV node block.

Quinidine : Quinidine should not be used concurrently with calcium

channel blockers because of reduced clearance of both drugs and potential

pharmacodynamic effects at the SA and AV nodes.

Miscellaneous : Diltiazem and verapamil inhibit hepatic cytochromes

CYP3A4, CYP2C9 andCYP2D6,possibly resulting in drug interactions.
http://en.wikipedia.org/wiki/Congestive_heart_failurehttp://en.wikipedia.org/wiki/Congestive_heart_failurehttp://en.wikipedia.org/wiki/Heart_blockhttp://en.wikipedia.org/wiki/Hypotensionhttp://en.wikipedia.org/wiki/Wolff-Parkinson-White_syndromehttp://en.wikipedia.org/wiki/Quinidinehttp://en.wikipedia.org/wiki/CYP3A4http://en.wikipedia.org/wiki/CYP2C9http://en.wikipedia.org/wiki/CYP2D6http://en.wikipedia.org/wiki/CYP2D6http://en.wikipedia.org/wiki/CYP2C9http://en.wikipedia.org/wiki/CYP3A4http://en.wikipedia.org/wiki/Quinidinehttp://en.wikipedia.org/wiki/Wolff-Parkinson-White_syndromehttp://en.wikipedia.org/wiki/Hypotensionhttp://en.wikipedia.org/wiki/Heart_blockhttp://en.wikipedia.org/wiki/Congestive_heart_failure


5/25

Side Effects:

A red, blistering skin rash, swelling in your hands or feet

trouble in breathing, slow heartbeats, fast or pounding heartbeat

dizziness, fainting, itching,

upper stomach pain, loss of appetite, dark urine, clay-colored stools,

jaundice

severe skin reaction -- fever, sore throat, swelling in your face or tongue,

burning in your eyes, skin pain, followed by a red or purple skin rash that

spreads) and causes blistering and peeling.

Less serious diltiazem side effects may include:

headache, dizziness, weakness, tired feeling, nausea

upset stomach, sore throat, cough, stuffy nose, flushing

Dosage:

The dose of Diltiazem in Supraventricular tachycardias is 0.25 mg/kg slow IV

push. Most commonly, a 20 mg IV dose is given to the average size patient

Dosing Information :

Usual Adult Diltiazem Dose for Hypertension:

Initial dose: 30 to 60 mg orally 3 to 4 times a day.

Maintenance dose: 180 to 360 mg orally/day in divided doses.

Initial bolus doses : 0.25 mg/kg as a bolus administered over 2 minutes.

A second bolus of 0.35 mg/kg may be used if necessary.

Initial infusion dose : 5 mg/hr.

Maintenance infusion dose : The infusion rate may be increased in 5 mg/hr increments up

to 15 mg/hr.
http://en.wikipedia.org/wiki/Supraventricular_tachycardiahttp://en.wikipedia.org/wiki/Supraventricular_tachycardia


6/25

Usual Adult Diltiazem Dose for Atrial Fibrillation:

Initial dose (oral): 30 to 60 mg orally 3 to 4 times a day.


Initial dose (IV): 0.25 mg/kg actual body weight bolus over 2 minutes. If necessary, a second

bolus of 0.35 mg/kg ABW may be given. In some cases, an infusion of diltiazem 5 mg/hour

may be started, and advanced in 5 mg/hour increments to 15 mg/hour for up to 24 hours.

Usual Adult Diltiazem Dose for Atrial Flutter:



Initial dose (IV) : 0.25 mg/kg actual body weight bolus over 2 minutes. If necessary, a second

bolus of 0.35 mg/kg ABW may be given. In some cases, an infusion of diltiazem 5

mg/hour may be started, and advanced in 5 mg/hour increments to 15 mg/hour for up to

24 hours.

Usual Adult Diltiazem Dose for Supraventricular Tachycardia:



Initial dose (IV) : 0.25 mg/kg actual body weight bolus over 2 minutes. If necessary, a second

bolus of 0.35 mg/kg ABW may be given. In some cases, an infusion of diltiazem 5

mg/hour may be started, and advanced in 5 mg/hour increments to 15 mg/hour for up to

24 hours.

Usual Adult Diltiazem Dose for Angina Pectoris Prophylaxis:

Initial dose: 30 to 60 mg orally 3 to 4 times a day.



7/25

Excipients profile

Mannitol:

Mannitol occurs as a white, odourless, crystalline powder, or free-flowing granules. It

has a sweet taste, approximately as sweet as glucose and half as sweet as sucrose, and imparts a

cooling sensation in the mouth.

Description of mannitol

a) Synonyms

Cordycepic acid; E421; manna sugar; D-mannite; Mannite; Mannogem; Pearlitol.

b) Chemical name and CAS registry number

D-Mannitol [69-65-8]

c) Empirical formula and molecular weight

Empirical Formula : C6H14O6

Molecular weight : 182.17

d) Structural Formula

e) Functional Category

Diluent; diluent for lyophilized preparations; Sweetening agent; Tablet and Capsule

diluents; Tonicity agent.


8/25

Applications in pharmaceutical formulation or technology

In pharmaceutical preparations it is primarily used as a diluent (1090% w/w) in

tablet formulations, due to its non hygroscopic nature and may thus be used with moisture-

sensitive active ingredients. Mannitol may be used in direct-compression tablet applications, for

which the granular and spray-dried forms are available. Specific tablet applications include

antacid preparations, and Vitamin preparations. Mannitol is commonly used as an excipient in

the manufacture of chewable tablet formulations because of its negative heat of solution,

sweetness, and mouth feel.

Solubility of mannitol

Freely soluble in water. Practically insoluble in ether.

Incompatibilities of mannitol

Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride or

sodium chloride. Mannitol is incompatible with Xylitol infusion and may form complexes with

some metals such as Aluminum, Copper, and Iron. Reducing sugar impurities in mannitol have

been implicated in the oxidative degradation of a peptide in a lyophilized formation. Mannitol

was found to reduce the oral bioavailability of Cimetidine compared to sucrose.


9/25

Microcrystalline cellulose (MCC)

Microcrystalline cellulose occurs as a white, odourless, tasteless, crystalline

powder composed of porous particles.

Description of microcrystalline cellulose (MCC)

a) Synonyms

Avicel PH; Celex; Cellulose gel; Celphere; Ceolus KG; Crystalline cellulose; E460; Emcocel;

Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur.

b) Chemical name and CAS Registry Number

Cellulose [9004-34-6]


(C6H10O5) n 36 000, Where n 220.

d) Structural formula

e) Functional Category

Adsorbent, Suspending agent, Tablet and Capsule diluents, Tablet disintegrant.


10/25


Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a

binder/diluent in Oral tablet and capsule formulations where it is used in both wetgranulation and

direct compression processes. In addition to its use as a binder/diluent, microcrystalline cellulose

also has some lubricant and disintegrant properties that make it useful in tableting.

Solubility of microcrystalline cellulose

Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, dilute

acids, and most organic solvents.

Incompatibilities of MCC

Microcrystalline cellulose is incompatible with strong oxidizing agents.


11/25

Sodium starch glycolate

Sodium starch glycolate is a white to off-white, odourless, tasteless, freeflowing powder.

The Ph Eur 2005 states that it consists of oval or spherical granules, 30-100 m in diameter, with

some less-spherical granules ranging from 10-35 m in diameter.

Description of sodium starch glycolate

a) Synonyms

Carboxymethyl starch, Sodium salt; Explosol; Explotab; Glycolys; Primojel; Starch

carboxymethyl ether, Sodium salt; Tablo; Vivastar P.

b) Chemical name and CAS registry number

Sodium carboxymethyl starch [9063-38-1]


The PhEur 2005 describes three types of material: Types A and B occurs as the sodium

salt of a cross-linked partly O-carboxymethylated potato starch, containing 2.8-4.2% and 2.0-

3.4% of sodium respectively. Type C is the sodium salt of a cross-linked by physical

dehydration, partly Ocarboxymethylated starch containing 2.8-5.0% sodium. Sodium starch

glycolate may be characterized by the degree of substitution and cross linking. The molecular

weight is typically 5 105-1 10

6.

d) Structural formula


12/25

e) Functional category

Tablet and capsule disintegrant.


Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in

Capsule and Tablet formulations. It is commonly used in tablets prepared by either direct

compression or wet-granulation processes. The usual concentration employed in a formulation is

between 2% and 8%. Disintegration occurs by rapid uptake of water followed by rapid and

enormous swelling. Although the effectiveness of many disintegrants is affected by the presence

of hydrophobic

excipients such as lubricants, the disintegrant efficiency of sodium starch glycolate is

unimpaired. Increasing the tablet compression pressure also appears to have no effect on

disintegration time.

Solubility of sodium starch glycolate

Sparingly soluble in ethanol (95%); practically insoluble in water.

Incompatibilities sodium starch glycolate

Sodium starch glycolate is incompatible with ascorbic acid.


13/25

Literature review

Koizumi K et al., presented an invention, which related to rapidly dissolving tablets using

sublimation technique. Compressed tablets of Mannitol did not dissolve in water due to

the low porosity. To increase the porosity of tablets sublimation was done. Tablets were

prepared by direct compression containing mannitol and camphor. A high porosity was

achieved due to formation of many pores due to camphor sublimation. The compressed

tablets have high porosity (approximately 30%) rapidly dissolved within 15 seconds in

saliva.

Remon JP et al., prepared the rapidly disintegrating tablets by lyophilization. Tablets

contained hydrochlorothiazide, Maltrodextrin, hydroxyethylcellulose and gelatine. The

solutions were poured into blisters and freeze dried. Maltrodextrin could be a filler of

choice for the production of lyophilized tablets as freeze-drying due to amorphous

network, which dissolved in the water with seconds. They evaluated gelatine, xanthan

gum and hydroxyethylcellulose a binding agents in the formulation of freeze dried tablets

with Maltrodextrin as filling agents.

Nayak SM et al., prepared fast dissolving tablets of Promethazine theoclate using

effervescent melt, super disintegration addition and melt technologies.Tablets from

effervescent melt and super disintegration addition technique released 92 % and 89 % of

the drug at the end of 10 min.

Shirwaiker AA et al., prepared fast disintegrating tablets of Atenolol. The preparation

contained an active ingredient, sugar (mannitol), superdisintegrant and dicalciumphosphate. Required quantities of each ingredient were weighed, mixed and prepared the

tablets by dry granulation. All the formulation had disintegration time of less than 70

seconds. Among the three superdisintegrant Ac-Di-Sol showed the highest efficacy.

Formulation containing 10 % Ac-Di-Sol showed the least disintegration time of 30 2

seconds compare to Explotab and Polyplasdone X.


14/25

Amin PD et al., presented an invention, which relates to fast disintegration tablets for oral

administration. Taste masked adsorbents of Ofloxacin were prepared using cationic

exchange resins. Taste evaluation of tablets showed complete masking of the bitterness of

Ofloxacin. The taste-masked complex of the Ofloxacin was further incorporated into

mouth dissolve tablets in combination with Metronidazole benzoate. All the formulation

exhibited an in vitro dispersion time less than 50 seconds.

Chaudhari PD et al., prepared fast dissolving tablets of Famotidine. In this study the

bitter taste of Famotidine was masked using drug: Eudragit E 100 in different ratios (1:1

to 1:10). For taste masking the ratio was optimized to 1:4 by time intensity. The different

superdisintegrant (Ac-Di-Sol, Polyplasdone) with their varying concentration were used

for disintegration of tablets in mouth. The formulation containing 2 % of Ac-Di-Sol and

Polyplasdone showed 91.89 % and 101.07 % release respectively in 12 min

Halakatti PK et al., formulated rapidly disintegrating tablets of Domperidone by applying

two methods. Sodium starch glycolate and treated agar used as superdisintegrants in mass

extrusion technique and treated agar method respectively.

Shirwaikar A et al., formulated and evaluated fast dissolving tablets of Granisetron

hydrochloride by direct compression method using superdisintegrants. A combination of

mannitol and silicified microcrystalline cellulose (SMCC) in the ration 70:30 was used in

the study. Study concluded that crospovidone and croscarmellose sodium are better

disintegrant for formulation of fast dissolving tablets of Granisetron HCl.

Vijaya KS et al., prepared Meloxicam rapidly disintegrating tablets by direct

compression. The tablets were prepared with three superdisintegrant like SSG, Ac-Di-Sol

and L-HPMC. The hardness of tablets was found to be less than 10% and disintegration


15/25

time of tablets was found to be less than 1 minute, except LHPMC.In-vitro drug release

study showed enhance dissolution rate compared to pure Meloxicam.


16/25

Materials and equipments

Analytical methods

Formulation of fast dispersable Tablets Of Diltiazem Hydrochoride

MATERIALS & EQUIPMENTS

The following materials those were either AR/LR grade or the best possible

pharmaceutical grade were used as supplied by the manufacturer.

S.No Materials Category

1

2

3

4

5

6

7

Diltiazem

Potato Strach

Primogel

Micro Crystalline Cellulose

Mannitol

Magnesium Stearate

Talc

Active Ingredient

Disintegrant

Super Disintegrant

Directly Compressible Vehicle

Directly Compressible Vehicle

Lubricant

Glidant


17/25

ANALYTICAL METHODS

Determination of max of Diltiazem Hydrochloride by UV analysis

25 mg of Diltiazem Hydrochloride was accurately weighed and dissolved in 25 ml

of Distilled Water to get 1 mg/ml solution. This solution was further diluted to get 6g/ml. UV

spectrum was recorded in the wavelength range of 200 - 400 nm. The l max of drug was

determined by UV-Visible Spectrophotometer using Distilled Water as a blank.

Construction Of Calibration Curve Of Diltiazem Hydrochloride

25mg of Diltiazem Hydrochloride was accurately weighed and dissolved in 25ml of

water to get 1mg/ml solution. From this Solution,1ml was taken and dissolved in 10ml Distilled

Water. This solution was then serially diluted with Distilled water to give solutions of

concentration ranging from 2 mg/ml to 10 mg/ml. The absorbances of these solutions were

measured at 240 nm using Distilled Water as table blank and standard graph was plotted.

S.No Equipment

1

2

3

4

5

6

Monsanto Hardness Tester

Friability Tester

Tablet Dissolution Tester (USP)

Tablet Disintegration Test Machine

Tablet Punching Machine

UV-Visible Spectrophotometer


18/25

Physical Properties

Angle of Repose ()

The frictional forces in a loose powder can be measured by the angle of repose (). It is an

indicative of the flow properties of the powder. It is defined as the maximum angle possiblebetween the surface of a pile of powder and the horizontal plane. Angle of repose was

determined by using funnel method. Powder was poured from funnel, which can be raised

vertically until a maximum cone height, h, was obtained. Diameter of heap, D, was measured.

The repose angle, , was calculated by formula,

= Tan-1 (2h/D)

Flow properties for different values of angle of repose are given below.

S.No Angle Of Repose Flow

1

2

3

4

40

Excellent

Good

Moderate (addition of 0.2% glident is required)

Poor

Table : Relationship between Powder Flow and Angle of Repose

Bulk Density (Db)

It is the ratio of total mass of powder to the bulk volume of powder. It was measured by pouring

the weighed amount of powder (passed through standard sieve #20) into a measuring cylinder

and the initial volume was noted. From this, the bulk density is calculated according to the

formula mentioned below. It is expressed in g/ml and is given by,

Db = M / V0

Where, M is the mass of powder

V0 is the bulk volume of the powder.


19/25

a. Tapped Density (Dt)

It is the ratio of total mass of powder to the tapped volume of powder. The volume was measured

by tapping the powder for 500 times. Then the tapping was done for 750 times and the tapped

volume was noted, if the difference between these two volumes is less than 2%. And if it is more

than 2%, tapping is continued for 1250 times and tapped volume was noted. Tapping was

continued until the difference between successive volumes is less than 2% (in a bulk density

apparatus). It is expressed in g/ml and is given by,

Dt = M / Vt

Where, M is the mass of powder

Vt is the tapped volume of the powder.

b. Compressibility Index (Carrs Consolidation Index)

One of the method of measurement of free flowing powder is compressibility as computed from

density of a powder. It was calculated by using the formula,

% Compressibility = [Tapped density-bulk density/tapped density] x 100

Percentage Compressibility Flow Description

5-15

12-16

18-21

23-28

28-35

35-38

>40

Excellent (free flowing granules)

Excellent (free flowing granules)

Fair (powdered granules)

Poor (very fluid powder)

Poor (fluid cohesive powder)

Very poor (fluid cohesive powder)

Extremely poor (cohesive powder)

Table : Relationship between Powder Flow and Percentage Compressibility


20/25

c. Hausner Ratio

Hausner ratio is an indirect index of ease of powder flow. If the hausner ratio of powder is near

to 1.25, indicates better powder flow. It is calculated by the formula,

Hausner Ratio = Dt / DbWhere, Db = Bulk density of the powder

Dt = Tapped density of the powder

Table : Relationship between Powder Flow and Hausner Ratio

Hausner Ratio Flow Description

1-1.11

1.12-1.18

1.19-1.25

1.26-1.34

1.35-1.45

1.46-1.56

Excellent

Good

Fair

Passable

Poor

Very Poor


21/25

Formulation And Development of Dispersible Tablet

Of Diltiazem Hydrochloride

Formulation development:

Formulation of Diltiazem Hydrochloride Dispersible tablets by direct compression involve use of

mannitol, and microcrystalline cellulose as diluent, mannitol also used as sweetener. Talc as

glident and magnesium stearate as lubricant. Sodium starch glycolate (Primojel) was used as

superdisintegrant. To select best formulation effective concentration various batches were taken

at different concentration range from 4 to 8 % w/w for each superdisintegrant.

Formulations:

Formulation 1:

S.No Ingridents

Formulations

F1 F2 F3

1

2

3

4

5

6

7


Potato Strach

Primogel

Magnesium Stearate

Talc

Micro Crystalline Cellulose

Mannitol

30

18

3.8

3.6

3.6

60.5

60.5

30

18

10.8

3.6

3.6

57

57

30

18

14.4

3.6

3.6

50.2

50.2

Table : Composition of formulations F1,F2 & F3


22/25

Procedure:

Mix Diltiazem Hydrochloride, Potato Strach, Primogel, Micro Crystalline Cellulose,

Mannitol And Sift Through # 80 Sieve

Load sifted material of Step-1 into Mortar & Pestle and mix for 15 Mins.

Lubricate the blend of Step-2 with # 80 passed Magnesium Stearate using Mortar &

Pestle for 2 minutes.

Add Talc as Glident to the Blend in Step-3 which was passed through # 80 Sieve

Compress the blend of Step-4 into tablet using Cad-mach Punching Machine to a tablet

of 180mg.

Formulation 2:

S.No Ingridents

Formulations

F4 F5 F6

1

2

3

4

5

6


Potato Strach

Primogel

Magnesium Stearate

Talc

Mannitol

30

18

3.8

3.6

3.6

121

30

18

10.8

3.6

3.6

114

30

18

14.4

3.6

3.6

110.4

Table : Composition of formulations F4,F5 & F6


23/25

Procedure:

Mix Diltiazem Hydrochloride, Potato Strach, Primogel, Mannitol And Sift Through # 80

Sieve

Load sifted material of Step-1 into Mortar & Pestle and mix for 15 Mins.

Lubricate the blend of Step-2 with # 80 passed Magnesium Stearate using Mortar &

Pestle for 2 minutes.

Add Talc as Glident to the Blend in Step-3 which was passed through # 80 Sieve

Compress the blend of Step-4 into tablet using Cad-mach Punching Machine to a tablet

of 180mg.

Evaluation of Dispersible Tablets Of Diltiazem

Hydrochloride:

General Appearance and Organoleptic PropertiesThe control of a general appearance of a tablet involves the measurement of

a number of attributes such as a tablets size, shape, color, presence or absence of anodour, taste,

surface texture, physical flaws and consistency, and legibility of any identifying markings.

Shape, Thickness and Dimension

Six tablets of each batch were selected and measured for thickness and diameter

using digital vernier calipers. The extent to which the thickness of each tablet deviated from 5% of the standard value was determined. Hardness of the tablet was determined by Monsanto

Hardness Tester. The tester consists of a barrel containing a compressible spring held between

two plungers. The lower plunger is placed in contact with the tablet, and zero reading is taken.

The upper plunger is then forced against a spring by turning a threaded bolt until the tablet

fractures. As the spring is compressed, a pointer rides along a gauge in the barrel to indicate the


24/25

force. The force of fracture is recorded, and the zero force reading is deducted from it. Six tablets

from each batch were selected and evaluated, and the average value with standard deviation was

recorded.

Friability Test

It is the phenomenon whereby tablet surfaces are damaged and/or show evidence

of lamination or breakage when subjected to mechanical shock or attrition. The friability of

tablets was determined by using Roche Friabilator. It is expressed in percentage (%). Ten tablets

were initially weighed (Winitial) and transferred into friabilator. The friabilator was operated at

25 rpm for 4 minutes or run up to 100 revolutions. The tablets were weighed again (Wfinal). The

percentage friability was then calculated by,

F = WinitialWfinal x 100

W initial

% Friability of tablets less than 1% is considered acceptable. The friability is expressed as the

loss of mass and it is calculated as a percentage of the initial mass.

Weight Variation Test

Weigh 20 tablets selected at random and calculate the average weight. Not

more than two of the individual weights deviate from the average weight by more than the

percentage shown in table 10 and none deviates by more than twice that percentage.

Average weight of tablet Percentage deviation

130 mg or less

More than 130 mg but less than 324 mg

324 mg or more

10

7.5

5

Table : IP Standards for percentage weight variation


25/25

Disintegration Time

The disintegration time for all formulations was carried out using

LABINDIA tablet disintegration test apparatus. Six tablets were placed individually in each tube

of disintegration test apparatus. The water was maintained at a temperature of 372C and time

taken for the entire tablet to disintegrate completely was noted.

Drug Release Studies

In vitro drug release studies were carried out by using LABINDIA

Dissolution Test Apparatus DS8000 using paddle stirrer at rotation speed of 50 rpm. The drug

release profile from tablets (n=3) of each formulation was studied in 900 ml of distilled water

maintained at 37 0.5C. Aliquots of 5 ml of dissolution medium were withdrawn at specific

time intervals (5, 10, 15, 20, 25,30,40,50 and 60 minutes), filtered and the amount of drug in the

samples was estimated using UV-Visibile spectrophotometer at wave length of 240nm and

results were reported.

Documents

Formulation and Evaluation of Glipizide